Moody's: Celgene view to positive

Moody's Investors Service said it revised the outlook on Celgene Corp. to positive from stable.

At the same time, Moody's affirmed Celgene's existing ratings, including the Baa2 senior unsecured rating and the Prime-2 commercial paper rating.

Expanding use of Revlimid and pending approvals of Apremilast in psoriatic arthritis and Abraxane in pancreatic cancer should sustain good growth momentum," Moody's senior vice president Michael Levesque said in a news release. "If pipeline execution is combined with conservative financial policies and healthy credit ratios, Moody's could upgrade Celgene's credit ratings."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.